Cochrane · systematic review · CD013001
Corneal collagen cross‐linking for bacterial infectious keratitis
Davis, SA, Bovelle, R, Han, G, et al. · Cochrane Database of Systematic Reviews · 2020 · Cochrane Library
Eyes and VisionAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
7
current version
GRADE rated
4
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 3 · 42.9%Very low 2 · 28.6%Low 2 · 28.6%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
PACK‐CXL with standard therapy compared with standard therapy alone for bacterial keratitis
Population: participants of any age with confirmed cases of bacterial keratitis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Proportion of participants with re‐epithelialization and complete healing with or without scar formation at 4 to 8 weeks Assessed by slit‐lamp biomicroscopy PACK‐CXL with standard therapy vs standard therapy alone | no estimate extracted | 15 participants | Very low Downgraded: risk of bias, imprecision |
Proportion of participants with BCVA of 20/100 or better at 4 to 8 weeks Assessed using a logMAR chart PACK‐CXL with standard therapy vs standard therapy alone | no estimate extracted | 12 participants | Very low Downgraded: risk of bias, imprecision |
Mean change from baseline in BCVA at 4 to 8 weeks Assessed using a logMAR chart PACK‐CXL with standard therapy vs standard therapy alone | no estimate extracted | 0 participants | Ungraded |
Proportion of participants with a reduction in corneal infiltrate at 4 to 8 weeks Assessed by outcome assessors PACK‐CXL with standard therapy vs standard therapy alone | no estimate extracted | 0 participants | Ungraded |
Proportion of participants with reduction in intraocular inflammation at 4 to 8 weeks Assessed by corneal keratic precipitates, anterior chamber cellular reaction, or other appropriate measure PACK‐CXL with standard therapy vs standard therapy alone | no estimate extracted | 0 participants | Ungraded |
Proportion of participants with treatment failure at 4 to 8 weeks Assessed by outcome assessors PACK‐CXL with standard therapy vs standard therapy alone | no estimate extracted | 1 study · 32 participants | Low Downgraded: risk of bias, imprecision |
Proportion of participants with adverse events at 4 to 8 weeks Assessed by outcome assessors PACK‐CXL with standard therapy vs standard therapy alone | no estimate extracted | 1 study · 32 participants | Low Downgraded: risk of bias, imprecision |